Contributor Disclosures for Persistent Hyperinsulinemic Hypoglycemia of Infancy

Role Name Disclosure Details Author  Robert S Gillespie, MD, MPH, Pediatric Nephrologist, Department of Nephrology, Driscoll Children's Hospital Nothing to disclose Details Coauthor  Stephen Ponder, MD, CDE, Director, Division of Pediatric Endocrinology, Department of Pediatrics, Driscoll Children's Hospital; Professor, Texas A&M College of Medicine Nothing to disclose Details Medical Editor  Thomas A Wilson, MD, Professor of Clinical Pediatrics, Department of Pediatrics; Director of Pediatric Endocrinology, Division of Pediatric Endocrinology, Department of Pediatrics, State University of New York at Stony Brook Nothing to disclose Details Pharmacy Editor  Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc Pfizer Inc Avanir Pharma Details Managing Editor  George P Chrousos, MD, FAAP, MACP, MACE, Professor and Chair, Department of Pediatrics, Athens University Medical School Nothing to disclose Details CME Editor  Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences Nothing to disclose Details Chief Editor  Stephen Kemp, MD, PhD, Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas and Arkansas Children's Hospital Genentech, Inc. Pfiser, Inc. Details Contributor Disclosure Contributor: Contributor Disclosure: Robert S Gillespie, Author  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Stephen Ponder, Coauthor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Thomas A Wilson  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Off label or investigational use of medication CONTRIBUTOR DISCLOSURE FORM Contributor Name: Mary L Windle  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Pfizer Inc Stock Investment from broker recommendation   Avanir Pharma Stock Investment from broker recommendation   Off label or investigational use of medication Contributor Disclosure Contributor: Contributor Disclosure: George P Chrousos, Managing Editor  The contributor discloses no conflict of interest.  Contributor Disclosure Contributor: Contributor Disclosure: Merrily P M Poth, CME Editor  The contributor discloses no conflict of interest.  CONTRIBUTOR DISCLOSURE FORM Contributor Name: Stephen Kemp  DECLARATION STATEMENT I and/or my spouse/partner have no financial interest with any organization that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. I and/or my spouse/partner have a financial interest/arrangement with one or more organization(s), including but not limited to the organization(s) supporting this activity, that could be perceived as a real or apparent conflict of interest in the context of the subject of this activity. COMMERCIAL INTEREST (Name of Organization) Self Spouse/ Partner NATURE OF RELEVANT FINANCIAL RELATIONSHIP What was received?* For what role?** Genentech, Inc. Honoraria Speaking and teaching   Pfiser, Inc. Honoraria Consulting   Off label or investigational use of medication